Www.cpme.eu CPME Comité Permanent des Médecins Européens Standing Committee of European Doctors Doctors and industry - European perspective International.

Slides:



Advertisements
Similar presentations
CPME Comité Permanent des Médecins Européens Standing Committee of European Doctors 6 th European Patients Rights Day – Active Ageing Citizens.
Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Ethics review and oversight for better governance of health research Amar Jesani Indian Journal of Medical Ethics Centre for Studies in Ethics and Rights.
MEETING OF THE UEMS ADVISORY COUNCIL ON CME Brussels. 24 November 2007 CONFLICT OF INTERESTS IN CME HOW IS IT REGULATED ? Helios Pardell. MD Director of.
Good Medical Practice Evidence to use for Appraisal Good Medical Practice 2006.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
ROLE OF THE PHYSICIAN IN THE APPROVAL PROCESS Stephanie de Bono MD PhD Medical Advisor, Eli Lilly.
European Union of Medical Specialists November 18, 2011 Conference John McLoughlin Chairman, European Medical Technology Industry Association (EUCOMED)
5/5/2015Software Engineering Code of Ethics1 Software Engineering Code of Ethics and Professional Practice Dr. Bob Weber CEG 460 / 660 Wright State University.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Advertising of rx medicinal products to the general public The case MSD Sharpe & Dohme GmbH vs. Merckle GmbH (C-316/09) Judgment of the ECJ of 5 May 2011.
Post-trial Access to Treatment by Patients participating in Clinical Trials Presented by Dr T K S Letlape Chairman: South African Medical Association President-Elect:
بسم الله الرحمن الرحيم. THE TITLE “INTRODUCTION”
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
Year 11 R and S Ethics Great Ethical Thinkers. Codes of Ethics in Society.
Research Ethics John Porter London School of Hygiene and Tropical Medicine.
External Influences on Prescribing Practice Karen Ford.
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Internal Auditing and Outsourcing
Put your organisation’s logo here. Conflicts of Interest A conflict occurs when the interests of one role/ position/ relationship are not aligned with.
9/8/201519/8/ Sep-15 1 CONFLICT OF INTEREST CONFLICT OF INTEREST Proposed Code Of Conduct for IAP CoI Advisors, Office Bearers & Members Prof. A.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Prof. György BAZSA, former president Hungarian Accreditation Committee (HAC) CUBRIK Workshop IV Beograd, 13 March, 2012 European Standards and Guidelines.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Medical ethics and undocumented migrants Milosz Swiergiel, NORP (IFMSA-Sweden) and Mirte Sprengers, NORP (IFMSA-The Netherlands) Small Working Group on.
The Eighth Asian Bioethics Conference Biotechnology, Culture, and Human Values in Asia and Beyond Confidentiality and Genetic data: Ethical and Legal Rights.
PAB/ICAJ Seminar1 The Public Accountancy Board & The Institute of Chartered Accountants of Jamaica Sustaining the Knowledge of Public Accountants - Seminar.
Research Conflicts of Interest: Identifying and Minimizing COI from the Perspective of Faculty July 30, 2009 PonJola Coney, MD Senior Associate Dean for.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Chapter 19: Ethical Responsibilities Chapter 19 Ethical Responsibilities.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Retha Britz Copyright 2013 All rights reserved for this presentation 1 Other important considerations for RECs Retha Britz.
Introduction Clinical trials Why clinical trials? Process of a clinical trial Informed consent Patients‘ interests Rights and protection Study Registers.
A survey of the Assessment of the General Practitioners ’ View Points about the Physician Charter Hashemi Fatemeh, Amini Mitra, and Saberfirousi Mehdi.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
COCIR Code of Conduct Nicole DENJOY COCIR Secretary General.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Standards of competition law in Member States of the European Union. The conceptual definition of a consumer - The consequence of understanding the terminology.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
F8: Audit and Assurance. 2 Designed to give you knowledge and application of: Section A: Audit Framework and Regulation Section B: Internal audit Section.
F Designed to give you knowledge and application of: Section A: Business organisational structure, governance & management A1. The business organisation.
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 6 CH 5 ISO MANAGEMENT RESPONSIBILITY Philippe Bauwin Medical.
Claude JANIZZI Chairman of the Lanzarote Committee
A capacity building programme for patient representatives
The IVD Australia Code of Conduct Edition 2.1
Making the Connection ISO Master Class An Overview.
Disclosure UK Talking about Transparency.
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Enrolling in Clinical Trials
STRESS TESTS and TAIWAN PEER REVIEW PROCESS
Within Trial Decisions: Unblinding and Termination
Disclosure UK Talking about Transparency.
3rd Joint General Assembly
AGREEMENT FOR TRANSPARENCY The Case of Mexico
CPME Activities UEMS Council meeting Dr Jacques de HALLER
Industry Induction Course
Evidence to use for Appraisal Good Medical Practice 2006
Patient information sheet & Principles of Good Clinical Practice
Presentation transcript:

CPME Comité Permanent des Médecins Européens Standing Committee of European Doctors Doctors and industry - European perspective International Conference “Transparency in medicine”, Bucharest, 17 October 2012 Konstanty Radziwill MD, PhD, CPME president

Cooperation between the medical profession and the medical industry is important and necessary at all stages of the development and use of medicines/devices to secure safety of patients and efficacy of therapy.

Facts Medical industry supports doctors in their work and professional development for the benefit of the patients. Industry employs physicians as their consultants and experts.

Parties of cooperation CPME - Standing Committee of European Doctors (30 national medical associations and 8 cooperating international medical organizations from Europe) EFPIA - European Federation of Pharmaceutical Industries and Associations (33 national associations and 35 leading pharmaceutical companies) Eucomed - European Medical Technology Industry Association (30 national associations and 62 corporate members representing design firms, manufacturers and suppliers of medical technology industry)

Result "Joint Declaration on Cooperation of Physicians and the pharmaceutical industry", Brussels, 8 June 2005 "Joint Declaration on Cooperation of Physicians and Medical Technology Industry" - in development

Areas of the CPME/EFPIA declaration Product information and promotion of approved medicines Meetings (education) organized or sponsored by industry Clinical research Consultancy and affiliations

Product information and promotion of approved medicines Industry must: provide honest and up-to-date information regarding their products, accurately describing their advantages and disadvantages based on current scientific evidence; make sure that sales representatives and personnel providing information are adequately qualified and trained;

Product information and promotion of approved medicines Industry must: disclose clinically relevant scientific data about their products at request of physicians; follow reports concerning their products after the medicine is available on the market and disclose important observations to doctors without delay;

Product information and promotion of approved medicines Industry must: not advertise medicines before they have been granted a marketing authorisation; not offer unjustified hospitality - gifts/benefits should be inexpensive and must be relevant to the practice of medicine.

Product information and promotion of approved medicines Physicians must: not ask for gifts/benefits from the industry; not accept unjustified hospitality - gifts/benefits should be inexpensive and must be relevant to the practice of medicine; report on adverse reactions of medicines.

Meetings (education) organized or sponsored by industry Pharmaceutical companies may arrange or sponsor educational meetings for doctors. Such events must have a clear educational content. The information rendered at any meeting should be based on scientific and medically relevant data. Activities, which form part of systematic CPD should be reviewed and certified by relevant bodies.

Meetings (education) organized or sponsored by industry In an announcement the purpose of the event should be clearly stated. It should be indicated whether the event is reviewed and certified. Venue of a meeting should be appropriate for the scientific purpose of the meeting, and should not involve travelling beyond what is needed. Industry may pay for lecturers, study material and facilities that are needed for the meeting. It can also pay for travelling and lodging for participants but not for any accompanying persons.

Meetings (education) organized or sponsored by industry Hospitality should be generally acceptable, reasonable and strictly limited to the purpose of the event. Sponsoring or organising of sporting or entertainment events is prohibited. The same principles shall apply also for activities taking place outside Europe when European doctors are involved.

Clinical research Cooperation between the pharmaceutical industry and the medical profession in conducting studies and clinical trials is essential to the development of medicinal products, for an in-depth knowledge of them and for their optimal use in the patient’s interest.

Clinical research All partners in a clinical trial must follow ethical and professional principles and guidelines, such as the WMA’s Declaration of Helsinki and ICH’s Good Clinical Practice guidelines; Each trial must pursue a scientific and therapeutically relevant aim. No trial should be performed primarily for promotional purposes. The aim of the trial must always be improvement of therapy, diagnostic methods and/or medical knowledge for the best of patients;

Clinical research The aim of the trial must be stated beforehand. Research protocols must be drafted in such a way as to ensure that this aim is achieved and that the conclusions of the study are valid; The sponsor has to be disclosed to the patients recruited to the study; A physician must not receive payment or other benefits for only referring patients to clinical trial;

Clinical research A physician may receive compensation for his work in a trial. The compensation must be related to the work done, and must be disclosed to the ethical committee reviewing the study protocol. The compensation must not be linked to any expected result of the study; All efficacy and safety results on marketed products should be honestly published irrespective of the outcome, at least in summary form on the Internet, within one year after the product received its marketing authorisation. Also other results of clinical importance should be published;

Clinical research In publications, lectures and other presentations the sponsor has to be disclosed; When giving presentations on trials a doctor has to disclose his connections with all companies in the therapeutic field covered.

Consultancy and affiliations Industry may ask physicians to act as consultants. In this capacity they can give service or expert advice to industry. Connections to the pharmaceutical industry of this kind must not compromise the clinical autonomy of the consulting or affiliated doctor, who always has to abide by the ethical duty to make medical decisions independently and practise medicine for the benefit of patients.

Payment for a consultancy assignment should relate directly to the work performed. When consulting physicians are presenting views or results to other parties, which concern the medico- pharmacological field of the consultancy assignment, a declaration of interest should be presented to ensure transparency. Consultancy and affiliations

Life Better do not participate in meetings that are not accredited. Pay attention to the meetings organized very far or in very attractive places. Do not accept sponsoring in the events of recreational, cultural or sporting character and of travel/participation of the accompanying persons. Do not expect gifts when dealing with representatives of the industry. Do not accept valuable gifts (especially not related to medical practice) and excessive hospitality.

Life Inform representatives of the industry about adverse reactions and in such situations expect explanation and assistance. When conducting clinical trials stick to the generally applicable rules in this area (especially the Declaration of Helsinki and the Good Clinical Practice guidlines) and in particular the rule that every trial must be accepted by the relevant ethics committee.

Life Clinical trial must have a clearly defined objective, the protocol must follow it. Remuneration of a doctor performing any kind of work for industry must be proportionate to the work done and can not be related to the results of the study. Research should be published regardless of their outcome.

Before accepting a gift, hospitality, service or support from a representative of medical industry......ask yourself three questions: after: American College of Physicians–American Society of Internal Medicine

What Would My Patients Think about This Arrangement?

What Is the Purpose of the Industry Offer?

What Would My Colleagues Think about This Arrangement?

Vă mulţumesc foarte mult pentru atenţie! Konstanty Radziwill, CPME